PharmaEssentia Corporation
6446
Rank in Stocks
#1424
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Share Price
$37.20
Market Cap
$15.39B
Change (1 day)
1.30%
Change (1 year)
144.58%
Country
TW
Trade PharmaEssentia Corporation (6446)
Category
Healthcare
Stock price history for PharmaEssentia Corporation (6446)
Highest end of day price: $37.68 on 2026-10-01
Lowest end of day price: $4.95 on 2014-03-01
Lowest end of day price: $4.95 on 2014-03-01
Stock price history of PharmaEssentia Corporation from 2014 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 77.64% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.15 | 21.02% |
DE
|
|
| $41.46 | 47.41% |
JP
|
|
| $212.49 | 23.19% |
CH
|
|
| $19.19 | -0.09% |
IN
|
